Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
???displayArticle.abstract???
BACKGROUND AND PURPOSE: Subunit-specific modulators of gamma-aminobutyric acid (GABA) type A (GABA(A)) receptors can help to assess the physiological function of receptors with different subunit composition and also provide the basis for the development of new drugs. Valerenic acid (VA) was recently identified as a beta(2/3) subunit-specific modulator of GABA(A) receptors with anxiolytic potential. The aim of the present study was to generate VA derivatives as novel GABA(A) receptor modulators and to gain insight into the structure-activity relation of this molecule.
EXPERIMENTAL APPROACH: The carboxyl group of VA was substituted by an uncharged amide or amides with different chain length. Modulation of GABA(A) receptors composed of different subunit compositions by the VA derivatives was studied in Xenopus oocytes by means of the two-microelectrode voltage-clamp technique. Half-maximal stimulation of GABA-induced chloride currents (I(GABA)) through GABA(A) receptors (EC(50)) and efficacies (maximal stimulation of I(GABA)) were estimated. Anxiolytic activity of the VA derivatives was studied in mice, applying the elevated plus maze test.
KEY RESULTS: Valerenic acid amide (VA-A) displayed the highest efficacy (more than twofold greater I(GABA) enhancement than VA) and highest potency (EC(50)= 13.7 +/- 2.3 microM) on alpha(1)beta(3) receptors. Higher efficacy and potency of VA-A were also observed on alpha(1)beta(2)gamma(2s) and alpha(3)beta(3)gamma(2s) receptors. Anxiolytic effects were most pronounced for VA-A.
CONCLUSIONS AND IMPLICATIONS: Valerenic acid derivatives with higher efficacy and affinity can be generated. Greater in vitro action of the amide derivative correlated with a more pronounced anxiolytic effect in vivo. The data give further confidence in targeting beta(3) subunit containing GABA(A) receptors for development of anxiolytics.
Atack,
The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics.
2005, Pubmed
Atack,
The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics.
2005,
Pubmed Baburin,
Automated fast perfusion of Xenopus oocytes for drug screening.
2006,
Pubmed
,
Xenbase Barnard,
International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function.
1998,
Pubmed Benke,
GABA A receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts.
2009,
Pubmed D'Hulst,
The complexity of the GABAA receptor shapes unique pharmacological profiles.
2009,
Pubmed Dias,
Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines.
2005,
Pubmed Drexler,
Distinct actions of etomidate and propofol at beta3-containing gamma-aminobutyric acid type A receptors.
2009,
Pubmed Groves,
The role of GABAbeta2 subunit-containing receptors in mediating the anticonvulsant and sedative effects of loreclezole.
2006,
Pubmed Johnston,
Modulation of ionotropic GABA receptors by natural products of plant origin.
2006,
Pubmed Khom,
Valerenic acid potentiates and inhibits GABA(A) receptors: molecular mechanism and subunit specificity.
2007,
Pubmed
,
Xenbase Khom,
Pharmacological properties of GABAA receptors containing gamma1 subunits.
2006,
Pubmed
,
Xenbase Krishek,
Homomeric beta 1 gamma-aminobutyric acid A receptor-ion channels: evaluation of pharmacological and physiological properties.
1996,
Pubmed
,
Xenbase Li,
Identification of a GABAA receptor anesthetic binding site at subunit interfaces by photolabeling with an etomidate analog.
2006,
Pubmed McKernan,
Which GABAA-receptor subtypes really occur in the brain?
1996,
Pubmed McKernan,
Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype.
2000,
Pubmed Methfessel,
Patch clamp measurements on Xenopus laevis oocytes: currents through endogenous channels and implanted acetylcholine receptor and sodium channels.
1986,
Pubmed
,
Xenbase Möhler,
GABA(A) receptor diversity and pharmacology.
2006,
Pubmed Möhler,
GABAA receptors in central nervous system disease: anxiety, epilepsy, and insomnia.
2006,
Pubmed NULL,
Guide to Receptors and Channels (GRAC), 4th Edition.
2009,
Pubmed Olsen,
International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update.
2008,
Pubmed Olsen,
GABA A receptors: subtypes provide diversity of function and pharmacology.
2009,
Pubmed Ramharter,
Total synthesis of valerenic acid, a potent GABAA receptor modulator.
2009,
Pubmed Rudolph,
Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes.
1999,
Pubmed Sieghart,
Subunit composition, distribution and function of GABA(A) receptor subtypes.
2002,
Pubmed Sieghart,
Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes.
1995,
Pubmed Sieghart,
Structure, pharmacology, and function of GABAA receptor subtypes.
2006,
Pubmed Simon,
Analysis of the set of GABA(A) receptor genes in the human genome.
2004,
Pubmed Wingrove,
The modulatory action of loreclezole at the gamma-aminobutyric acid type A receptor is determined by a single amino acid in the beta 2 and beta 3 subunit.
1994,
Pubmed
,
Xenbase Wittmann,
Prodynorphin-derived peptides are critical modulators of anxiety and regulate neurochemistry and corticosterone.
2009,
Pubmed
